Biennial report

Study Groups

Title of the study group: EULAR Epidemiology and Registries Study Group

Study Group Leader’s name: Axel Finckh
Date of annual report submission: 01/2021

What we do: Summary of last year’s activities

Preliminary note: Because of the COVID-19 pandemic, most in-person meetings and study group activities between march 2020 and now had to be cancelled, which has severely impacted level of activity and the networking activities of this study group.

- Organisation of the **EULAR “Registries and Observational Data (RODS) Course”**: The 3rd course took place in Amsterdam in October 2019, the fourth course is planned to take place virtually in October 2021 and in person in the fall 2022 (Organisation: Elena Nikphorou, Aikaterini Chatzidionysiou, Axel Finckh et al.)
- Collaborative pharmacoepidemiologic studies on the incidence of **adverse events** on biological anti-rheumatic therapies (1-3).
- Collaborative studies on the **effectiveness of biologic** anti-rheumatic therapies (4-5).
- **EULAR Task Forces** on data harmonisation and core sets in various RMDs (6-7), and recommendations for the analysis and reporting of such data (8-9)
- Collaborative work relating to “**Method-oriented**” topics, such as handling of missing data (10), Mobile health technologies (11), “Big Data and artificial intelligence” (12-13)

References:

1) Lauper K, Mongin D, Bergstra SA, et al. « **Heterogeneity in adverse event assessment between countries participating in an international collaboration of registries of rheumatoid arthritis patients using Janus Kinase Inhibitors (the JAK-pot study)**”. Submitted to the EULAR 2021 congress.


4) K. Lauper, D. Mongin, S. A. Bergstra, et al. “**Comparative effectiveness of JAK-inhibitors, TNF-inhibitors, abatacept and IL-6 inhibitors in an international collaboration of registers of rheumatoid arthritis patients (the “JAK-pot” study)**”. Podium presentation at EULAR scientific meeting 2020. OP023 Ann Rheum Dis, volume 79, supplement 1, year 2020, page 146


